Education
About Us
Working with TipRanks
Follow Us
enVVeno Medical (NVNO)
NASDAQ:NVNO
NVNO Stock Chart & Stats
$0.36
-$0.06(-1.92%)
At close: 4:00 PM EST
$0.36
-$0.06(-1.92%)
Day’s Range― - ―
52-Week Range$8.67 - $196.70
Previous CloseN/A
Volume33.14K
Average Volume (3M)589.93K
Market Cap
$6.68M
Enterprise Value-$576.09K
Total Cash (Recent Filing)$30.95M
Total Debt (Recent Filing)$791.00K
Price to Earnings (P/E)―
Beta1.98
Next Earnings
May 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding655,606
10 Day Avg. Volume395,892
30 Day Avg. Volume589,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.09
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.17
Enterprise Value/Ebitda0.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-35
Revenue Forecast (FY)$7.00M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces near-term solvency risk and interest burden, preserving financial flexibility. For a device developer still in clinical stages, low leverage supports the ability to prioritize R&D and regulatory work without immediate refinancing pressure, aiding longer-term execution.
Cash RunwayA reported $31.5M in cash provides a tangible runway into 2027, enabling planned clinical activities and regulatory alignment for next-generation programs. This reduces the immediacy of dilutive financing and allows the company to advance human testing and endpoint discussions with regulators.
Next-gen Product Ready For TestingHaving a transcatheter enVVe program ready for human testing represents a structural product pivot toward less-invasive therapy, aligned with industry trends. If clinical data are positive, this could materially improve commercial feasibility versus the surgical VenoValve approach.
Bears Say
No Commercial RevenueThe company is not generating sales and reports negative gross profit, indicating costs exceed any product-derived income. This structural lack of commercialization means prolonged dependence on external funding until product approvals and market adoption occur.
Significant Cash BurnSustained negative operating and free cash flow (~-$17.2M TTM) shows the business consumes capital to fund operations and trials. Persistent cash burn heightens reliance on external financing, increasing dilution risk and creating execution pressure to achieve regulatory milestones before runway lapses.
Regulatory SetbackAn unfavorable FDA PMA appeal decision is a material regulatory setback that delays commercialization and raises uncertainty on approval pathways. It forces resource reallocation, protocol redesign, and renewed regulator engagement, increasing time and cost to market and execution risk.
enVVeno Medical News
NVNO FAQ
What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was $8.67 and its highest was $196.70 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is $6.68M.
When is enVVeno Medical’s upcoming earnings report date?
enVVeno Medical’s upcoming earnings report date is May 04, 2026 which is in 61 days.
How were enVVeno Medical’s earnings last quarter?
Currently, no data Available
Is enVVeno Medical overvalued?
According to Wall Street analysts enVVeno Medical’s price is currently Overvalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 655,606 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of enVVeno Medical?
Currently, no hedge funds are holding shares in NVNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
enVVeno Medical
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.